DTC/DTP + Telemedicine – The Next Big Thing in Pharma?
How should pharma leaders adapt to this new DTC/DTP-driven world, and what role does telemedicine play in closing the loop from awareness to access?
DTC/DTP + Telemedicine: The Next Big Thing in Pharma?
Archbow Consulting recently partnered with Omnicom Health to raise awareness about a buzz-worthy case study examining the recent trend of Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) models—and what these shifts mean for the future of the pharmaceutical industry.
Discover how DTC/DTP and telemedicine are transforming healthcare access. Dive into real-world insights on digital health solutions, improved patient outcomes, and the evolving landscape of care delivery. Read the full case study here.
For additional insights on this topic, you may also enjoy the following:
Launching a Specialty Therapy? Don’t Fly Blind.
Launch a specialty therapy with confidence. Archbow Consulting’s fair market value benchmarking and negotiation guidance help pharma manufacturers assess distribution and service fees.
Medical Benefit Patient Support Programs: The Questions That Shape the Right Model
Explore seven key questions for designing medical benefit patient support programs that align with patient needs, provider workflows, and real-world access and reimbursement challenges.
Mastering 3PL Economics for Manufacturers
Discover how specialized 3PL cost analysis helps manufacturers identify pricing discrepancies and negotiate with confidence.
SUBSCRIBE
Subscribe to receive news and updates from Archbow Consulting
|
|


